---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-163050"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:56:49.885438+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies announces positive TSHA-102 clinical data; IDMC approves early advancement to high dose cohort

## Summary
- Longer-term adult data (up to 52 weeks) show durable improvements in motor, communication, autonomic, and seizure domains.
- Adult patient 1 gained ability to sit unassisted for first time in over a decade; patient 2 seizure-free for 8.5 months at 25% lower anti-seizure medication.
- Initial pediatric data (up to 22 weeks) show early developmental gains: improved hand function, gait, and communication via eye-gaze device.
- IDMC approved early advancement to high dose cohort in pediatric trial; dosing expected Q3 2024 after review of adult high dose safety.
- TSHA-102 generally well-tolerated with no drug-related serious adverse events or dose-limiting toxicities in either trial.

## SEC filing metadata
- accession: 0001193125-24-163050
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/0001193125-24-163050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/d851091d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-163050
- JSON: https://secwatch.observer/filing/0001193125-24-163050.json
- Plain text: https://secwatch.observer/filing/0001193125-24-163050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.